Tumor Treating Fields for the Treatment of Brainstem Gliomas
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Emory University
- Study ID
- NCT05310448
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Optune device — DEVICEWear Optune device
Study Details
This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with cancer cell division. TTFields may prevent growth or decrease size of gliomas in patients
Key Dates
- Start date
- May 11, 2022
- Status verified
- Sep 2025
- Primary completion
- Sep 1, 2026
- Completion
- May 1, 2027
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (tumor treating fields)After completion of standard of care radiation therapy, patients wear the Optune device for 18 hours per day for 12 months in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Incidence of adverse events [ Time Frame: Up to 12 months after TTFields started ]
Central Contacts
- Jim Zhong, MD404-778-3473
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Emory Proton Therapy Center | Atlanta | Georgia | 30308 | Jim Zhong, MD (PRINCIPAL_INVESTIGATOR) |
| Emory Saint Joseph's Hospital | Atlanta | Georgia | 30342 | Jim Zhong, MD (PRINCIPAL_INVESTIGATOR) |
| Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | Jim Zhong, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Atlanta, GA
By condition
By specialty
Related Studies
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)PHASE3 · Recruiting · Jazz Pharmaceuticals · Phoenix, Arizona
- Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid TumorsRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)PHASE1/PHASE2 · Recruiting · Plus Therapeutics · Manhasset, New York